Quick Answer
Fulcrum Therapeutics, Inc. reported Common Stock Shares Outstanding of 66.58 million shares for the year ending 2025.
- Fulcrum Therapeutics, Inc. showed an increase of +23.4% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Fulcrum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: 1.87 million shares | Q3 2019: 22.56 million shares | Q1 2020: 22.79 million shares | Q2 2020: 27.22 million shares | Q3 2020: 27.28 million shares | Q1 2021: 32.59 million shares | Q2 2021: 32.66 million shares | Q3 2021: 40.53 million shares | Q1 2022: 40.68 million shares | Q2 2022: 41.01 million shares | Q3 2022: 52.05 million shares | Q1 2023: 61.76 million shares | Q2 2023: 52.10 million shares | Q3 2023: 52.10 million shares | Q1 2024: 62.14 million shares | Q2 2024: 62.25 million shares | Q3 2024: 53.94 million shares | Q1 2025: 53.98 million shares | Q2 2025: 54.09 million shares | Q3 2025: 54.11 million shares.
- Over the full 8 years of available data (2018 to 2025), Fulcrum Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 4,092.7%.
- Historical annual values: Fiscal year 2025: 66.58 million shares | Fiscal year 2024: 53.97 million shares | Fiscal year 2023: 61.92 million shares | Fiscal year 2022: 52.10 million shares | Fiscal year 2021: 40.63 million shares | Fiscal year 2020: 27.94 million shares | Fiscal year 2019: 22.65 million shares | Fiscal year 2018: 1.59 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: